# US 2013/0323210 A1 · Infectious schmallenberg virus from cloned cdnas and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0323210 A1
- Document ID: US20130323210A1
- Status: Published application
- Kind: A1
- Application number: 13/904,506
- Filed: 2013-05-29
- Published: 2013-12-05
- Earliest claimed: 2012-06-01
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Inventors: Ilona REIMANN; Martin BEER; Kerstin WERNIKE
- Web page: https://patentgrep.com/patent/US20130323210A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 2760/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/12043: viral genome or elements thereof as genetic vector
- C12N 2760/12051: Methods of production or purification of viral material
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the complete genome of an infectious Schmallenberg virus (SBV) useful for studying viremia and diseases caused by SBV in ruminants, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of viremia and diseases caused by SBV.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising the complete genomic sequence of a Schmallenberg virus (SBV) genome segment, wherein said molecule comprises a nucleic acid sequence selected from the group consisting of:
a nucleic acid sequence having at least 97.8% sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7,
a nucleic acid sequence having at least 82.2% sequence identity with the nucleic acid sequence of SEQ ID NO:2,
a nucleic acid sequence having at least 93% sequence identity with the nucleic acid sequence of SEQ ID NO:3, and
any combinations thereof.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1 comprising the complete genomic sequence of the S segment of Schmallenberg virus, wherein said molecule comprises a nucleic acid sequence having at least 97.8% sequence identity with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:7.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1 comprising the complete genomic sequence of the M segment of Schmallenberg virus, wherein said molecule comprises a nucleic acid sequence having at least 82.2% sequence identity with the nucleic acid sequence of SEQ ID NO:2.

### Claim 4 (depends on 1)

The nucleic acid molecule of claim 1 comprising the complete genomic sequence of the L segment of Schmallenberg virus, wherein said molecule comprises a nucleic acid sequence having at least 93% sequence identity with the nucleic acid sequence of SEQ ID NO:3.

### Claim 5 (depends on 2, 3, 4)

A combination of two nucleic acid molecules selected from the group consisting of the nucleic acid molecule of claim 2, the nucleic acid molecule of claim 3, and the nucleic acid molecule of claim 4.

### Claim 6 (depends on 2, 3, 4)

A combination of the nucleic acid molecule of claim 2, the nucleic acid molecule of claim 3, and the nucleic acid molecule of claim 4.

### Claim 7 (depends on 6)

The combination of claim 6, wherein the nucleic acid molecules contained therein are capable of producing infectious Schmallenberg virus when transfected into cells.

### Claim 8 (depends on 7)

The combination of claim 7, wherein the virus is able to induce SBV viremia in mammals and/or insects.

### Claim 9 (depends on 1)

A cDNA construct comprising a cDNA molecule according to claim 1.

### Claim 10 (depends on 2, 3, 4)

A combination of two different cDNA constructs selected from the group consisting of
a cDNA construct comprising a cDNA molecule according to claim 2,
a cDNA construct comprising a cDNA molecule according to claim 3, and
a cDNA construct comprising a cDNA molecule according to claim 4.

### Claim 11 (depends on 2, 3, 4)

A combination of the cDNA constructs comprising:
a cDNA construct comprising a cDNA molecule according to claim 2,
a cDNA construct comprising a cDNA molecule according to claim 3, and
a cDNA construct comprising a cDNA molecule according to claim 4.

### Claim 12 (depends on 9)

An RNA transcript of the cDNA construct of claim 9.

### Claim 13 (depends on 2, 3, 4)

A combination of two RNA transcripts selected from the group consisting of:
an RNA transcript of a cDNA construct comprising a cDNA molecule according to claim 2,
an RNA transcript of a cDNA construct comprising a cDNA molecule according to claim 3, and
an RNA transcript of a cDNA construct comprising a cDNA molecule according to claim 4.

### Claim 14 (depends on 2, 3, 4)

A combination of the RNA transcripts comprising:
an RNA transcript of a cDNA construct comprising a DNA molecule according to claim 2,
an RNA transcript of a cDNA construct comprising a cDNA molecule according to claim 3, and
an RNA transcript of a cDNA construct comprising the cDNA molecule according to claim 4.

### Claim 15 (depends on 9)

A cell transfected with the cDNA construct of claim 9.

### Claim 16 (depends on 10)

A cell transfected with a combination of cDNA constructs according to claim 10.

### Claim 17 (depends on 11)

A cell transfected with a combination of cDNA constructs according to claim 11.

### Claim 18 (depends on 12)

A cell transfected with the RNA transcript of claim 12.

### Claim 19 (depends on 13)

A cell transfected with a combination of RNA transcripts according to claim 13.

### Claim 20 (depends on 14)

A cell transfected with a combination of RNA transcripts according to claim 14.

### Claim 21 (depends on 15)

A Schmallenberg virus produced by the cell of claim 15.

### Claim 22 (depends on 16)

A Schmallenberg virus produced by the cell of claim 16.

### Claim 23 (depends on 17)

A Schmallenberg virus produced by the cell of claim 17.

### Claim 24 (depends on 18)

A Schmallenberg virus produced by the cell of claim 18.

### Claim 25 (depends on 19)

A Schmallenberg virus produced by the cell of claim 19.

### Claim 26 (depends on 20)

A Schmallenberg virus produced by the cell of claim 20.

### Claim 27 (depends on 1)

A Schmallenberg virus whose genome comprises a nucleic acid molecule according to claim 1.

### Claim 28 (depends on 5)

A Schmallenberg virus whose genome comprises a nucleic acid molecule according to a combination of nucleic acid molecules according to claim 5.

### Claim 29 (depends on 9)

A method for producing a Schmallenberg virus comprising transfecting a cell with the cDNA construct of claim 9.

### Claim 30 (depends on 10)

A method for producing a Schmallenberg viruses comprising transfecting a cell with the cDNA construct of the combination of cDNA constructs according to claim 10.

### Claim 31

A method for producing a Schmallenberg viruses comprising transfecting a cell with the cDNA construct of the combination of cDNA constructs according to claimll.

### Claim 32 (depends on 12)

A method for producing a Schmallenberg virus comprising transfecting a host cell with the RNA transcript of claim 12.

### Claim 33 (depends on 13)

A method for producing a Schmallenberg virus comprising transfecting a host cell with the RNA transcript of the combination of RNA transcripts according to claim 13.

### Claim 34 (depends on 14)

A method for producing a Schmallenberg virus comprising transfecting a host cell with the RNA transcript of the combination of RNA transcripts according to claim 14.

### Claim 35 (depends on 1)

A composition comprising a nucleic acid molecule of claim 1 suspended in a suitable amount of a pharmaceutically acceptable diluent or excipient.

### Claim 36 (depends on 5)

A composition comprising a combination of nucleic acid molecules according to claim 5, suspended in a suitable amount of a pharmaceutically acceptable diluent or excipient.

### Claim 37 (depends on 15)

The cells according to claim 15, wherein the cell contains an RNA polymerase.

### Claim 38 (depends on 37)

The cells according to claim 37, wherein the cell expresses the RNA polymerase.
